Syndax Pharmaceuticals (SNDX) Misses Q3 EPS by 13c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.84), $0.13 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Sun Communities names Ileana McAlary as general counsel and EVP
• Ennis (EBF) Reports In-Line Q1 EPS